Objective: Interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) is currently one of the preferred treatment options for advanced ovarian, fallopian tube or peritoneal cancer. This study was conducted to evaluate the clinical efficacy and safety of dose-dense paclitaxel plus carboplatin therapy (ddTC therapy) as NAC for these cancers. Patients and methods: A retrospective study was conducted in 25 patients with Stage III/IV ovarian, fallopian tube or peritoneal cancer who received ddTC therapy as NAC. For ddTC therapy, paclitaxel (80 mg/m 2 ) was administered intravenously on Days 1, 8 and 15 and carboplatin (AUC 6.0 mg/ml × min) was administered intravenously on Day 1 every 3 weeks. IDS was performed after three cycles of ddTC therapy, and ddTC therapy was also continued after surgery. Results: With ddTC therapy as NAC, the response rate was 92% and disease progression did not occur in any patient. Grade 4 hematologic toxicity and ≥Grade 3 non-hematologic toxicity both occurred in 8% of the patients, but no patient discontinued NAC because of adverse events. When IDS was performed, the complete surgery rate was 64% and the optimal surgery rate was 96%. ≥Grade 3 perioperative complications occurred in 16% of the patients, but there were no perioperative deaths. Median overall survival was 35.7 months and median progression-free survival was 17.7 months. Conclusion: This study showed that ddTC therapy was considerably effective and tolerable as NAC. The complete surgery rate was high with IDS, and perioperative complications were acceptable.
Introduction
Among malignant tumors of the female genital organs, ovarian cancer ranks first for mortality. In Japan, both the number of ovarian cancer patients and deaths from this cancer have been increasing (1) . The tumor stage is considered to be an important prognostic factor of treatment for ovarian cancer, and the outcome is rather poor for patients with Stage II or more advanced disease (2) . Thus, developing an optimal treatment for patients with advanced disease is an important issue in the management of ovarian cancer. Whereas, fallopian tube cancer and primary peritoneal cancer are less common diseases that are classified as Müllerian carcinoma originating from the epithelium of the primordial perivisceral cavity. Because the biological behavior and pathological characteristics of these tumors are similar to those of ovarian cancer (3, 4) , these diseases are usually managed according to the same treatment policies.
In patients with advanced ovarian, fallopian tube or peritoneal cancer, it is recommended that initial surgical treatment include maximal primary debulking surgery (PDS) aimed at complete removal of all macroscopic tumors (complete surgery) in addition to staging (5) . On the other hand, if maximal tumor reduction is considered to be impossible to accomplish by initial surgery, performing interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) is the preferred treatment option because non-inferiority of the overall survival (OS) has been confirmed by several Phase III randomized trials comparing PDS with IDS after NAC (6, 7) .
Combination therapy with a platinum agent plus a taxane is the standard chemotherapy provided after initial surgery for advanced ovarian, fallopian tube or peritoneal cancer. Similar chemotherapy regimens are also often used for NAC, because administration of regimens that include both a platinum agent and a taxane has been shown a better outcome of treatment (8, 9) . However, in previous Phase III randomized trials, the NAC regimen was only specified as platinum-based chemotherapy. To improve outcomes, it is important to determine the optimal NAC regimen that can maximize the efficacy of IDS.
The Japanese Gynecologic Oncology Group reported in their Phase III study (JGOG3016) that the progression-free survival (PFS) and OS for patients with FIGO Stages II-IV advanced ovarian, fallopian or peritoneal cancer were significantly longer for the group receiving paclitaxel every week as dose-dense TC therapy (ddTC therapy) than those for the group receiving standard tri-weekly combination therapy with paclitaxel plus carboplatin (TC therapy) (10, 11) . Because NAC was also included in this study, ddTC therapy was given to some patients as NAC, but the efficacy of this therapy as NAC was not investigated separately.
Accordingly, this retrospective study was performed to assess the clinical efficacy and safety of ddTC therapy as NAC for Japanese women with advanced ovarian, fallopian tube or peritoneal cancer.
Patients and methods

Patients
The subjects of this study were 25 patients with Stage III/IV ovarian, fallopian tube or primary peritoneal cancer who received ddTC therapy as NAC from January 2012 to December 2014 at the Department of Obstetrics and Gynecology of Keio University Hospital (Tokyo, Japan). The inclusion criteria were as follows: patients who were clinically estimated to have FIGO Stage III or IV cancer by diagnostic imaging, a definite histologic diagnosis by cytology or tissue biopsy, adequate function of vital organs, no uncontrolled serious complications, no active synchronous double cancer and no prior treatment for the target disease.
Treatment
Each cycle of ddTC therapy included intravenous infusion of paclitaxel (80 mg/m 2 ) and carboplatin (AUC 6.0 mg/ml × min) on Day 1, followed by intravenous infusion of paclitaxel (80 mg/m 2 ) on Day 8
and Day 15. This regimen was repeated every 3 weeks. Appropriate dose reduction was performed for febrile neutropenia, Grade 4 hematologic toxicity, and Grade 3 or worse non-hematologic toxicity. After three cycles of ddTC therapy as NAC, IDS was performed at a time when adverse events due to chemotherapy were considered to have been fully resolved. As IDS, gynecological oncologists performed maximal debulking surgery according to the latest version of the treatment guidelines. The surgical procedure not only included bilateral adnexectomy with hysterectomy and omentectomy, but also peritoneal cytodiagnosis/biopsy plus pelvic/paraaortic lymph node biopsy/dissection. Resection of disseminated intraperitoneal lesions, peritoneal stripping and combined resection of other organs such as the intestines was also performed if necessary.
After IDS, the same ddTC therapy was also provided as postoperative chemotherapy, commencing when perioperative complications were considered to have been fully resolved. Treatment was terminated if the patient was evaluated to have achieved a complete response (CR) at the end of three postoperative cycles (six cycles in total). Two further cycles could be added (eight cycles in total) if the patient showed a partial response (PR) after six cycles.
Treatment was discontinued if there was disease progression or if intolerable serious adverse events occurred.
Evaluation of efficacy and safety
Data on the baseline characteristics of the patients, clinical response to ddTC therapy as NAC, tolerability of NAC, adverse events, IDS procedure/completeness of surgery, perioperative complications, PFS and OS were retrospectively collected from the hospital medical records for investigation.
The clinical efficacy of NAC was evaluated according to the Revised Response Evaluation Criteria in Solid Tumors (RECIST Guideline Version 1.1). The efficacy of NAC was evaluated at only one point, because surgery was performed immediately if chemotherapy was found to be effective. Treatment-related adverse events were evaluated in accordance with Common Terminology Criteria for Adverse Events, Version 4.0. PFS and OS curves were calculated by the Kaplan-Meier method.
Results
Baseline characteristics of the patients Table 1 shows the baseline characteristics of the 25 patients enrolled in this study. Their median age was 67 years (range: 42-81 years) and ECOG Performance Status was 0-1 in 24 patients (96%). The primary tumor was ovarian cancer in 17 patients (68%), fallopian tube cancer in one patient (4%), and peritoneal cancer in seven patients (28%). The most common histologic type was serous carcinoma, which was found in 21 patients (84%). The clinical stage was III in 17 patients (68%) and IV in eight patients (32%). Before treatment, the median serum CA125 level was 1 728 U/ml (range: 169-27 614 U/ml), and the median maximum diameter of the primary and metastatic tumors confirmed by diagnostic imaging was 6 cm (range: 1-15 cm).
Efficacy and toxicity of ddTC therapy as NAC Table 2 shows data on the clinical efficacy of NAC and adverse events that were observed during the NAC period. Based on RECIST Version 1.1 criteria, the response rate (complete and partial response rate) to ddTC therapy as NAC was 92% and none of the patients had progressive disease (PD). Disappearance of malignant effusions (ascites or pleural effusion) was noted clinically after NAC in 13 of the 24 patients (54%) with malignant effusions before treatment. Improvement of PS occurred after NAC in 7 of 10 patients (70%) whose PS was 1 or worse before treatment. After NAC, serum CA125 decreased to 25% or less of the baseline level (75% response) in 21 patients (84%) and was normalized in eight patients (32%).
Grade 4 hematologic toxicity occurred in two patients (8%), and Grade 3 or worse anemia was observed in 14 patients (56%). Administration of granulocyte colony-stimulating factor (G-CSF) or blood transfusion was needed in six patients (24%). Grade 3 or worse non-hematologic toxicity was noted in two patients (8%), with one having phlegmon and the other having hypokalemia.
Regarding the tolerability of NAC, the treatment period was prolonged due to adverse events in nine patients (36%) and dose reduction was needed in four patients (16%). However, discontinuation of treatment due to adverse events did not occur. The median interval from the day of completing NAC until IDS was 29 days (range: 14-52 days).
IDS procedures and complete surgery rate
For IDS, the median operating time was 349 min (range: 97-746 min). All surgical procedures, including the typical procedures required for staging (bilateral adnexectomy, total hysterectomy, omentectomy, pelvic lymph node dissection and paraaortic lymph node dissection) and resection of disseminated lesions and peritoneal stripping, could be performed in 20 patients (80%), while typical procedures excluding lymph node dissection were performed in four patients (16%). Only palliative surgery with construction of a stoma was performed in one patient (4%). Combined intestinal resection was required in seven patients (28%).
Complete surgery (no macroscopic residual tumor) was accomplished in 16 patients (64%) by IDS, while optimal surgery (residual tumor diameter 0-1 cm) could be achieved in 24 patients (96%) ( Table 3) .
Perioperative complications and postoperative chemotherapy
Blood transfusion was needed at the time of IDS in 17 patients (68%). Within 30 days after IDS, Grade 3 or worse postoperative complications were noted in four patients (16%), including intraperitoneal hemorrhage in two patients, ascites due to lymphorrhea in one patient, and hypotension in one patient. There were no perioperative deaths. The median interval from completion of IDS until the start of postoperative chemotherapy was 29 days (range: 20-44 days). The median total number of chemotherapy cycles including NAC and postoperative chemotherapy was six cycles (range: 3-8 cycles).
OS and PFS
The median observation period was 26.5 months (5.7-44.5 months). OS and PFS curves calculated by the Kaplan-Meier method are displayed in Figs 1 and 2 , respectively. Median OS was 35.7 months (5.7-44.5 months) and median PFS was 17.7 months (4.1-44.5 months).
Discussion
Clinical validation of ddTC therapy was based on the hypothesis that prolonging the duration of exposure to paclitaxel (increased dose density) would increase the antitumor effect more than elevating the blood level of paclitaxel by increasing the dose (increased dose intensity) (12) (13) (14) (15) (16) (17) . It was shown by a Phase III study (JGOG3016) that ddTC therapy delivering weekly doses of paclitaxel is more effective than standard tri-weekly TC therapy in which paclitaxel is administered every 3 weeks (10,11). At present, ddTC therapy is considered to be the most effective regimen for first-line chemotherapy.
To date, there were few previous reports that showed the tolerability and efficacy of ddTC therapy as NAC (18, 19) . Accordingly, we performed the present study to investigate the clinical efficacy and safety of ddTC therapy as NAC, including detailed clinical information about IDS following NAC.
Several reports have already been published concerning NAC for patients with advanced ovarian, fallopian tube or peritoneal cancer. The NAC regimen was only specified as three cycles of platinumbased chemotherapy in two Phase III studies (EORTC55971/NCIC OV13 (6) and CHORUS (7)) that confirmed non-inferiority of OS between IDS after NAC and PDS. In contrast, the NAC regimen was specified as four cycles of tri-weekly TC therapy in an ongoing Phase III study (JCOG0602) with a similar design (20) . There is currently no consensus about the optimal number of NAC cycles. In the JGOG3016 study, IDS could be performed after from two to four cycles of NAC. However, it was considered more appropriate to set three cycles of ddTC as NAC in the present study.
We found a response rate of 92% to ddTC therapy as NAC, and this high response rate may also be resulted in decreasing malignant effusions and improving the PS. Owing to the beneficial effect of NAC, IDS achieved a complete surgery rate (no macroscopic residual tumor) of 64%, and the optimal surgery rate (residual tumor diameter 0-1 cm) was 96%. These rates were respectively 51% and 81% in the EORTC55971/NCIC OV13 study (6) , 39% and 73% in the CHORUS study (7), and 55% and 71% in the JCOG0602 study (20) . Therefore, the results of IDS obtained in the present study were better than those reported previously. Similaly, previous studies also reported a high efficacy of ddTC therapy as NAC; Becker et al. showed that the response rate was 86% and the optimal surgery was 81% respectively (18). Ebata et al. indicated the complete surgery rate of 64% and optimal surgery rate of 74% (19) . These results, together with the current study, implied that the high response rate of ddTC therapy might contribute to easier and more efficient cytoreduction.
Median OS and PFS were, respectively, 35.7 and 17.7 months in the present study, 30.0 and 12.0 months in EORTC55971/NCIC OV13 (6), and 24.1 and 12.0 months in CHORUS (7) . Both OS and PFS were better in the present study than those in other trials. The residual tumor diameter at IDS as well as PDS has been reported to be closely correlated with the prognosis for ovarian cancer (6, (21) (22) (23) (24) (25) , making efforts to achieve complete or optimal surgery a very important part of the treatment strategy. Thus, the residual tumor diameter at IDS can be a surrogate marker of the outcome, and the high rate of complete surgery owing to the efficacy of ddTC therapy as NAC may have led to improvement of the prognosis.
Because three cycles of ddTC as NAC could be delivered in all of the patients, the tolerability of this regimen was acceptable. The incidence of anemia has been reported to be significantly higher with ddTC therapy than tri-weekly TC therapy. The JGOG3016 study showed that the incidence of Grade 3 or worse anemia was 69% in the ddTC therapy group and 44% in the tri-weekly TC therapy group (10) . In the present study, Grade 3 or worse anemia was also noted in 56% of the patients receiving NAC, and blood transfusion was needed in 16%. Appropriate control of anemia is considered to be essential for administration of NAC without delay and for safe IDS.
In the present study, the incidence of perioperative complications was 16.0% and there were no perioperative deaths. The incidence of these events was, respectively, 6.4% and 0.7% in EORTC55971/ NCIC OV13 (6), 14.0% and <1% in CHORUS (7) and 4.6% and 0% in JCOG0602 (20) . Thus, the incidence of perioperative complications was slightly higher in this study than in previous reports, but none of the complications were fatal. All patients recovered and were discharged from hospital without sequelae after appropriate management. The invasiveness of IDS after ddTC as NAC was considered to be acceptable.
In conclusion, we found that ddTC was considerably effective and tolerable as NAC, a high complete surgery rate was achieved by IDS, and perioperative complications were acceptable. To further improve prognosis for patients with advanced ovarian, fallopian tube or peritoneal cancer, it is necessary to find novel treatment regimens for controlling tumor more safely and effectively. 
